In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
As of close of business last night, Lexicon Pharmaceuticals Inc’s stock clocked out at $1.3, down -1.52% from its previous closing price of $1.32. In other words, the price has decreased by -$1.52 from its previous closing price. On the day, 1.04 million shares were traded. LXRX stock price reached its highest trading level at $1.35 during the session, while it also had its lowest trading level at $1.3.
Ratios:
To gain a deeper understanding of LXRX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.63 and its Current Ratio is at 5.64. In the meantime, Its Debt-to-Equity ratio is 0.54 whereas as Long-Term Debt/Eq ratio is at 0.53.
Upgrades & Downgrades
In the most recent recommendation for the company, Leerink Partners on March 05, 2025, Downgraded its rating to Market Perform and sets its target price to $1 from $2 previously.
On June 17, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $10.
On April 30, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $5.Leerink Partners initiated its Outperform rating on April 30, 2024, with a $5 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LXRX now has a Market Capitalization of 472418496 and an Enterprise Value of 421418272. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.67 while its Price-to-Book (P/B) ratio in mrq is 3.93. Its current Enterprise Value per Revenue stands at 5.947 whereas that against EBITDA is -7.813.
Stock Price History:
The Beta on a monthly basis for LXRX is 0.70, which has changed by 0.71428573 over the last 52 weeks, in comparison to a change of 0.13613915 over the same period for the S&P500. Over the past 52 weeks, LXRX has reached a high of $1.66, while it has fallen to a 52-week low of $0.28. The 50-Day Moving Average of the stock is -8.23%, while the 200-Day Moving Average is calculated to be 33.41%.
Shares Statistics:
It appears that LXRX traded 2.28M shares on average per day over the past three months and 1373400 shares per day over the past ten days. A total of 363.40M shares are outstanding, with a floating share count of 184.05M. Insiders hold about 49.37% of the company’s shares, while institutions hold 23.63% stake in the company. Shares short for LXRX as of 1764288000 were 24226907 with a Short Ratio of 10.61, compared to 1761868800 on 27704594. Therefore, it implies a Short% of Shares Outstanding of 24226907 and a Short% of Float of 18.620001.
Earnings Estimates
The dynamic stock of Lexicon Pharmaceuticals Inc (LXRX) is currently being evaluated by a team of 5.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.06, with high estimates of -$0.05 and low estimates of -$0.08.
Analysts are recommending an EPS of between -$0.16 and -$0.18 for the fiscal current year, implying an average EPS of -$0.17. EPS for the following year is -$0.26, with 5.0 analysts recommending between -$0.19 and -$0.32.
Revenue Estimates
A total of 4 analysts have provided revenue estimates for LXRX’s current fiscal year. The highest revenue estimate was $51.1M, while the lowest revenue estimate was $44.31M, resulting in an average revenue estimate of $47.72M. In the same quarter a year ago, actual revenue was $31.08M
